Q4

MARKSANS PHARMA LTD.

MARKSANSFY2519 May 2025

Revenue-89.6%

Net Profit-91.4%

OPM17.75%

P&L

Quarterly Consolidated

Revenue

-89.6%70.85

Expenditure

-89.3%60.89

Net Profit

-91.4%9.07

NPM 12.51%-15.5%EPS ₹2.00-13.4%

vs Q3 FY25

Informational and educational content only. Not investment advice.